91¹ú²ú¾«Æ·

91¹ú²ú¾«Æ·. (1).
ASH Letter to FDA re Draft Guidance on Decentralized Clinical Trials.
Retrieved from /advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-decentralized-clinical-trials.

91¹ú²ú¾«Æ·.
"ASH Letter to FDA re Draft Guidance on Decentralized Clinical Trials." Hematology.org.
/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-decentralized-clinical-trials
(label-accessed November 14, 2024).

"91¹ú²ú¾«Æ·."
ASH Letter to FDA re Draft Guidance on Decentralized Clinical Trials, 14 Nov. 2024 ,
/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-decentralized-clinical-trials.

Citation Manager Formats

• BibLaTeX
• Bookends
• EasyBib
• EndNote
• Mendeley
• Papers
• RIS
• Ref Manager
• RefWorks
• Zotero